Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Noriko Kamata"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
IBD
Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease
Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba, Maiko Ogawa, Taku Kobayashi, Masahide Oshita, Hiroki Tanaka, Keiji Ozeki, Sakuma Takahashi, Hiroki Kitamoto, Kazuhito Kani, Sohachi Nanjo, Takeshi Sugaya, Yuko Sakakibara, Toshihiro Inokuchi, Kazuki Kakimoto, Akihiro Yamada, Hisae Yasuhara, Yoko Yokoyama, Takuya Yoshino, Akira Matsui, Misaki Nakamura, Taku Tomizawa, Ryosuke Sakemi, Noriko Kamata, Toshifumi Hibi
Intest Res 2018;16(4):609-618.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00044
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients.
Methods
IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation.
Results
A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients.
Conclusions
H. pylori eradication therapy does not alter the short-term disease activity of IBD.

Citations

Citations to this article as recorded by  
  • Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry
    Thu Giang Le Thi, Katharina Werkstetter, Kallirroi Kotilea, Patrick Bontems, José Cabral, Maria Luz Cilleruelo, Michal Kori, Josefa Barrio, Matjaž Homan, Nicolas Kalach, Rosa Lima, Marta Tavares, Pedro Urruzuno, Zrinjka Misak, Vaidotas Urbonas, Sibylle Ko
    Helicobacter.2024;[Epub]     CrossRef
  • Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate?
    Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, Giovanna Palladino, Alessandro Federico, Rocco Maurizio Zagari
    Diseases.2024; 12(8): 179.     CrossRef
  • Bibliometric analysis of the correlation between H. pylori and inflammatory bowel disease
    Yantong Li, Limin Li, Wenmeng Yin, Juyi Wan, Xiaolin Zhong
    JGH Open.2024;[Epub]     CrossRef
  • Discussion on the common controversies of Helicobacter pylori infection
    Hang Yang, Yi Mou, Bing Hu
    Helicobacter.2023;[Epub]     CrossRef
  • Helicobacter pylori and Inflammatory Bowel Disease: An Unresolved Enigma
    Juris Pokrotnieks, Stanislav Sitkin
    Inflammatory Bowel Diseases.2023; 29(3): e5.     CrossRef
  • Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems
    Li Wang, Zheng-Min Cao, Li-Li Zhang, Xin-can Dai, Zhen-ju Liu, Yi-xian Zeng, Xin-Ye Li, Qing-Juan Wu, Wen-liang Lv
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Helicobacter pylori infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt
    Ekram W. Abd El-Wahab, Ebtessam I. Youssef, Ehab Hassouna
    BMJ Open.2022; 12(5): e057214.     CrossRef
  • Is the Presence of Helicobacter Pylori in the Colonic Mucosa, Provocative of Activity in Ulcerative Colitis?
    Javad Ranjbar, Bita Geramizadeh, Kamran Bagheri Lankarani, Zahra Jowkar, Mitra Mirzai, Elham Moazamian
    Clinical Pathology.2022;[Epub]     CrossRef
  • Helicobacter pylori infection and inflammatory bowel diseases
    Yu. P. Uspenskiy, N. V. Baryshnikova, A. N. Suvorov, A. V. Svarval
    Russian Journal of Infection and Immunity.2021; 11(1): 68.     CrossRef
  • Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer
    Yuji Fujita, Keiichi Tominaga, Takanao Tanaka, Takeshi Sugaya, Shigemi Yoshihara
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease
    Hussam Murad, Misbahuddin Rafeeq, Mahmoud Mosli, Mamdouh Gari, Mohammed Basheikh
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Extra-Gastric Manifestations of Helicobacter pylori Infection
    Antonietta G. Gravina, Kateryna Priadko, Paola Ciamarra, Lucia Granata, Angela Facchiano, Agnese Miranda, Marcello Dallio, Alessandro Federico, Marco Romano
    Journal of Clinical Medicine.2020; 9(12): 3887.     CrossRef
  • Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance
    Bekir Kocazeybek, Merve Kutlu Sakli, Pelin Yuksel, Mehmet Demirci, Reyhan Caliskan, Tevhide Ziver Sarp, Suat Saribas, Suleyman Demiryas, Fatma Kalayci, Huseyin Cakan, Hayriye Kirkoyun Uysal, Nesrin Gareayaghi, Sevgi Ergin, Yusuf Ziya Erzin, Kadir Bal, İhs
    Journal of Medical Microbiology .2019; 68(4): 566.     CrossRef
  • Review:Helicobacter pyloriand extragastric diseases
    Francesco Franceschi, Marcello Covino, Claire Roubaud Baudron
    Helicobacter.2019;[Epub]     CrossRef
  • 8,629 View
  • 148 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Brief Communication
IBD
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
Tadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe
Intest Res 2018;16(3):494-498.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.494
PDFSupplementary MaterialPubReaderePub

Citations

Citations to this article as recorded by  
  • Partial Enteral Nutrition in the Management of Crohn’s Disease: A Systematic Review and Meta-Analysis
    Aleksandra Jatkowska, Bernadette White, Konstantinos Gkikas, John Paul Seenan, Jonathan MacDonald, Konstantinos Gerasimidis
    Journal of Crohn's and Colitis.2025;[Epub]     CrossRef
  • Patient experiences with and adherence to Crohn’s disease exclusion diet in Dutch Crohn’s disease patients: a cohort study
    Fleur T. R. Wijers, Suzanne M. C. van Zundert, Charlotte M. Verburgt, Nikki van der Kruk, Johan E. Van Limbergen, Nicolette J. Wierdsma
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Nutrition and dietary therapy in paediatric inflammatory bowel disease
    Konstantinos Gerasimidis
    Clinical Nutrition ESPEN.2025; 67: 233.     CrossRef
  • Pancreatic Enzyme Replacement Therapy Improves Exclusive Enteral Nutrition Related Diarrhea in Crohn's Disease: A Prospective Randomized Trial
    Jian Kang, Jing Wang, Juan Su, Wei Wang, Yueyue Lu, Zhishun Tang, Liping Zou, Anning Yin, Jiao Li, Haixia Ren, Qian Zhou, Huipeng Wan, Ping An
    United European Gastroenterology Journal.2025;[Epub]     CrossRef
  • Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn’s disease
    Sisi Zhou, Zeyu Huang, Wenjing Hou, Yiting Lin, Jing Yu
    Inflammation Research.2024; 73(2): 199.     CrossRef
  • Role of diet in prevention versus treatment of Crohn’s disease and ulcerative colitis
    Emma P Halmos, Lihi Godny, Julie Vanderstappen, Chen Sarbagili-Shabat, Vaios Svolos
    Frontline Gastroenterology.2024; : flgastro-2023-102417.     CrossRef
  • Immunoregulatory Effects of Elemental Diet and Its Ingredient, Tryptophan, via Activation of the Aryl Hydrocarbon Receptor in Mice
    Atsuhito Kubota, Shungo Imai, Ryoichi Aoyagi, Wataru Murase, Masaru Terasaki, Mitsuru Sugawara, Yoh Takekuma, Hiroyuki Kojima
    International Journal of Molecular Sciences.2024; 25(6): 3448.     CrossRef
  • Real-world evidence of combined treatment of biologics and exclusive enteral nutrition in patients with ileum-dominant Crohn's disease: A multicenter study
    Wei Wang, Anning Yin, Jing Wang, Jiao Li, Jingyun Cheng, Jian Kang, Yaqing Xu, Yueyue Lu, Yuanping Yang, Juan Su, Qian Zhou, Ya Liu, Zhishun Tang, Haixia Ren, Weiwei Li, Weiguo Dong, Baoping Yu, Ping An
    Clinical Nutrition.2024; 43(6): 1291.     CrossRef
  • It’s Time to Change Tack in IBD Treatment
    Marcel A. Behr, Ildiko Mehes, Charles N. Bernstein
    Gastroenterology.2024; 167(6): 1065.     CrossRef
  • "Out of the box� new therapeutic strategies for Crohn�s disease: moving beyond biologics
    Ignacio Catalán-Serra, Pret Ricanek, Tore Grimstad
    Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
  • Nutritional Therapy Strategies in Pediatric Crohn’s Disease
    Charlotte M. Verburgt, Mohammed Ghiboub, Marc A. Benninga, Wouter J. de Jonge, Johan E. Van Limbergen
    Nutrients.2021; 13(1): 212.     CrossRef
  • Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
    Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
    Journal of Gastroenterology.2021; 56(6): 489.     CrossRef
  • Diet and nutrition in the management of inflammatory bowel disease
    Pabitra Sahu, Saurabh Kedia, Vineet Ahuja, Rakesh K. Tandon
    Indian Journal of Gastroenterology.2021; 40(3): 253.     CrossRef
  • Nutritional Aspects of Pediatric Gastrointestinal Diseases
    Teresa Di Chio, Christiane Sokollik, Diego G. Peroni, Lara Hart, Giacomo Simonetti, Franziska Righini-Grunder, Osvaldo Borrelli
    Nutrients.2021; 13(6): 2109.     CrossRef
  • Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
    Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
    Intestinal Research.2021; 19(3): 291.     CrossRef
  • Nutritional Therapies and Their Influence on the Intestinal Microbiome in Pediatric Inflammatory Bowel Disease
    Lara Hart, Charlotte M. Verburgt, Eytan Wine, Mary Zachos, Alisha Poppen, Mallory Chavannes, Johan Van Limbergen, Nikhil Pai
    Nutrients.2021; 14(1): 4.     CrossRef
  • Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
    Fumihito Hirai, Teruyuki Takeda, Yasumichi Takada, Masahiro Kishi, Tsuyoshi Beppu, Noritaka Takatsu, Masaki Miyaoka, Takashi Hisabe, Kenshi Yao, Tosiharu Ueki
    Journal of Gastroenterology.2020; 55(2): 133.     CrossRef
  • Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-
    Shinji Okabayashi, Taku Kobayashi, Toshifumi Hibi
    Journal of the Anus, Rectum and Colon.2020; 4(1): 1.     CrossRef
  • Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
    Ajit Sood, Arshdeep Singh, Ritu Sudhakar, Vandana Midha, Ramit Mahajan, Varun Mehta, Yogesh Kumar Gupta, Kirandeep Kaur
    Intestinal Research.2020; 18(2): 184.     CrossRef
  • Enteral nutrition in the biologic era: learn from yesterday, live for today, hope for tomorrow
    Tadakazu Hisamatsu
    Intestinal Research.2020; 18(2): 139.     CrossRef
  • Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals
    Jun Miyoshi, Daisuke Saito, Mio Nakamura, Miki Miura, Tatsuya Mitsui, Toru Kudo, Shinnosuke Murakami, Minoru Matsuura, Tadakazu Hisamatsu
    Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
  • Fool me once… treatment exposure to achieve remission in pediatric IBD
    Johan E. Van Limbergen, Bart G. P. Koot, J. Peter de Winter
    European Journal of Pediatrics.2020; 179(12): 1921.     CrossRef
  • Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease
    Esteban Sáez-González, Beatriz Mateos, Pedro López-Muñoz, Marisa Iborra, Inés Moret, Pilar Nos, Belén Beltrán
    Nutrients.2019; 11(5): 1062.     CrossRef
  • 7,698 View
  • 158 Download
  • 22 Web of Science
  • 23 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP